Matrivax Research

Matrivax is a biotechnology company that specialized in the development of novel vaccines using its proprietary Protein Capsular Matrix Vaccine (PCMV) platform. The PCMV technology was designed to create multivalent vaccines by non-covalently entrapping bacterial polysaccharides within a protein matrix, offering a more efficient and scalable alternative to traditional chemical conjugation methods. The company's primary focus was on infectious diseases, with its lead program, MVX-01, targeting Streptococcus pneumoniae. In 2021, Merck (MSD) acquired Matrivax and its PCMV platform to bolster its pneumococcal vaccine portfolio. This acquisition allowed Merck to integrate Matrivax's simplified manufacturing approach and broad-spectrum protection capabilities into its global vaccine development strategy.